Tuesday - April 14, 2026
GSK Presents Positive Data for B7-H4-Targeted ADC in Gynaecological Cancers
April 14, 2026
LONDON, England, April 14 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 12, 2026:

* * *

GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers

* Mocertatug rezetecan achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC) in BEHOLD-1 study

* Current treatment options ar . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products